At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 24 enrolled
Drug / intervention
Arimoclomol +1 moredrug
Likely dose
Arimoclomol 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis
In Brief
A Phase 3 clinical trial evaluating Arimoclomol and Placebo for Inclusion Body Myositis. Completed, enrolled 24 participants across 2 sites in 2 countries.
Detailed Summary
Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInclusion Body Myositis
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionSep 2012
TodayJul 2026
First PostedOct 9, 2008
Enrollment StartSep 1, 2008
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 17.7 years ago
Interventions
Arimoclomoldrug
Arimoclomol 100 mg TID for 4 months
Placeboother
Placebo for 4 months